目的了解抗血管內(nèi)皮生長(zhǎng)因子（VEGF）抗體對(duì)人肝癌的生長(zhǎng)抑制作用。方法在已建立的人肝癌裸鼠皮下種植瘤的瘤灶旁，注射抗VEGF抗體，觀察腫瘤生長(zhǎng)情況，用CD31的免疫組化方法檢測(cè)腫瘤內(nèi)部的微血管密度（iMVD），用原位末端轉(zhuǎn)移酶標(biāo)記技術(shù)檢測(cè)凋亡的腫瘤細(xì)胞。結(jié)果實(shí)驗(yàn)結(jié)束后1周，實(shí)驗(yàn)組和對(duì)照組腫瘤大?。ㄩL(zhǎng)×寬）是（26.46±19.81） mm2和（105.77±17.40） mm2（P＜0.001），2周后是（45.20±23.02） mm2和（150.77±77.41） mm2（P＜0.05），而此時(shí)腫瘤的iMVD是（2 311±120）個(gè)／mm2和（3 900±328）個(gè)／mm2 （P＜0.001）； 腫瘤細(xì)胞凋亡指數(shù)是15.31% 和 6.83%（P＜0.005）。結(jié)論抗VEGF抗體能通過(guò)抑制腫瘤微血管的生長(zhǎng)，抑制實(shí)驗(yàn)性人肝癌的生長(zhǎng)，其實(shí)質(zhì)是增加了腫瘤細(xì)胞凋亡。
引用本文： 解乃昌,李國(guó)威,王志亮,陸云飛. 抗血管內(nèi)皮生長(zhǎng)因子抗體對(duì)實(shí)驗(yàn)性肝癌的生長(zhǎng)抑制作用. 中國(guó)普外基礎(chǔ)與臨床雜志, 2002, 9(4): 242-245. doi: 復(fù)制
| 1. | 李曉明，湯釗猷，周鉻，等.血管內(nèi)皮細(xì)胞生長(zhǎng)因子的表達(dá)與肝細(xì)胞癌侵襲和轉(zhuǎn)移的關(guān)系 [J].中華腫瘤雜志，1998； 20（1）∶ 12. |
| 2. | Suzuki K, Hayashi N, Miyamoto Y, et al. Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma [J].Cancer Res, 1996; 56(13)∶ 3004. |
| 3. | Weidner N,Semple JP, Welch WR, et al. Tumour angiogenesis and metastasiscorrelation in invasive breast carcinoma [J]. N Engl J Med, 1991； 324（1）∶ 1. |
| 4. | Ueda M, Ueki K, Kumagai K, et al. Apoptosis and tumour angiogenesis in cervical cancer after preoperative chemotherapy [J]. Cancer Res, 1998; 58(11)∶ 2343. |
| 5. | Plate KH, Breier G, Weich HA, et al. Vascular endothelial growth factor and glioma angiogenesis:coordinate induction of VEGF receptors，distribution of VEGF protein and possible in vitro regulatory mechanisms [J].Int J Cancer, 1994; 59(4)∶ 520. |
| 6. | Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factorinduced angiogenesis suppresses tumour growth in vivo [J].Nature, 1993; 362(6423)∶ 841. |
| 7. | Newman PJ. The biology of PECAM1 [J]. J Clin Invest, 1997; 100(11 Suppl)∶ S25. |
| 8. | Folkman J. Tumour angiogenesis: therapeutic implications [J].N Engl J Med, 1971; 285(21)∶ 1182. |
- 1. 李曉明，湯釗猷，周鉻，等.血管內(nèi)皮細(xì)胞生長(zhǎng)因子的表達(dá)與肝細(xì)胞癌侵襲和轉(zhuǎn)移的關(guān)系 [J].中華腫瘤雜志，1998； 20（1）∶ 12.
- 2. Suzuki K, Hayashi N, Miyamoto Y, et al. Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma [J].Cancer Res, 1996; 56(13)∶ 3004.
- 3. Weidner N,Semple JP, Welch WR, et al. Tumour angiogenesis and metastasiscorrelation in invasive breast carcinoma [J]. N Engl J Med, 1991； 324（1）∶ 1.
- 4. Ueda M, Ueki K, Kumagai K, et al. Apoptosis and tumour angiogenesis in cervical cancer after preoperative chemotherapy [J]. Cancer Res, 1998; 58(11)∶ 2343.
- 5. Plate KH, Breier G, Weich HA, et al. Vascular endothelial growth factor and glioma angiogenesis:coordinate induction of VEGF receptors，distribution of VEGF protein and possible in vitro regulatory mechanisms [J].Int J Cancer, 1994; 59(4)∶ 520.
- 6. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factorinduced angiogenesis suppresses tumour growth in vivo [J].Nature, 1993; 362(6423)∶ 841.
- 7. Newman PJ. The biology of PECAM1 [J]. J Clin Invest, 1997; 100(11 Suppl)∶ S25.
- 8. Folkman J. Tumour angiogenesis: therapeutic implications [J].N Engl J Med, 1971; 285(21)∶ 1182.